KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of GoodwillCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)DivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Exchange Rate Effect (2017 - 2025)

Teva Pharmaceutical Industries' Exchange Rate Effect history spans 9 years, with the latest figure at -$10.0 million for Q4 2025.

  • For the quarter ending Q4 2025, Exchange Rate Effect rose 91.74% year-over-year to -$10.0 million, compared with a TTM value of $21.0 million through Dec 2025, up 112.07%, and an annual FY2025 reading of $21.0 million, up 112.07% over the prior year.
  • Exchange Rate Effect for Q4 2025 was -$10.0 million at Teva Pharmaceutical Industries, down from -$9.0 million in the prior quarter.
  • The five-year high for Exchange Rate Effect was $146.0 million in Q4 2022, with the low at -$123.0 million in Q2 2022.
  • Average Exchange Rate Effect over 5 years is -$21.7 million, with a median of -$32.0 million recorded in 2021.
  • Biggest YoY gain for Exchange Rate Effect was 404.17% in 2022; the steepest drop was 2360.0% in 2022.
  • Tracing TEVA's Exchange Rate Effect over 5 years: stood at -$48.0 million in 2021, then skyrocketed by 404.17% to $146.0 million in 2022, then tumbled by 53.42% to $68.0 million in 2023, then tumbled by 277.94% to -$121.0 million in 2024, then skyrocketed by 91.74% to -$10.0 million in 2025.
  • Per Business Quant, the three most recent readings for TEVA's Exchange Rate Effect are -$10.0 million (Q4 2025), -$9.0 million (Q3 2025), and -$5.0 million (Q2 2025).